MedPath

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

Phase 2
Completed
Conditions
Kidney Cancer
Metastatic Cancer
Registration Number
NCT00006483
Lead Sponsor
Alliance for Clinical Trials in Oncology
Brief Summary

RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung.

PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who have kidney cancer that has spread to the lung.

Detailed Description

OBJECTIVES:

* Determine the 4-month progression-free survival rate and overall survival rate in patients with metastatic renal cell carcinoma to the lung treated with aerosolized sargramostim (GM-CSF).

* Determine the toxicity of this regimen in these patients.

* Determine the immunomodulatory effects of this regimen in terms of natural killer cells cytotoxicity, and T-cell, B-cell, and dendritic cell activation markers.

OUTLINE: This is a multicenter study.

Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.

Patients are followed for disease progression and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 21-48 patients will be accrued for this study within 7-20 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Determine the 4-month progression-free survival rate4 months
Secondary Outcome Measures
NameTimeMethod
Determine the 4-month overall survival rate4 months

Trial Locations

Locations (24)

CCOP - Scottsdale Oncology Program

🇺🇸

Scottsdale, Arizona, United States

CCOP - Illinois Oncology Research Association

🇺🇸

Peoria, Illinois, United States

CCOP - Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

CCOP - Cedar Rapids Oncology Project

🇺🇸

Cedar Rapids, Iowa, United States

CCOP - Iowa Oncology Research Association

🇺🇸

Des Moines, Iowa, United States

Siouxland Hematology-Oncology

🇺🇸

Sioux City, Iowa, United States

CCOP - Wichita

🇺🇸

Wichita, Kansas, United States

CCOP - Ochsner

🇺🇸

New Orleans, Louisiana, United States

CCOP - Ann Arbor Regional

🇺🇸

Ann Arbor, Michigan, United States

CCOP - Duluth

🇺🇸

Duluth, Minnesota, United States

Scroll for more (14 remaining)
CCOP - Scottsdale Oncology Program
🇺🇸Scottsdale, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.